Assembly Biosciences (NASDAQ:ASMB - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data before the market opens on Thursday, August 14th. Analysts expect the company to announce earnings of ($1.63) per share and revenue of $5.30 million for the quarter.
Assembly Biosciences (NASDAQ:ASMB - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($1.33) EPS for the quarter, beating the consensus estimate of ($1.73) by $0.40. The firm had revenue of $9.63 million for the quarter, compared to analyst estimates of $5.30 million. Assembly Biosciences had a negative return on equity of 149.01% and a negative net margin of 117.20%. On average, analysts expect Assembly Biosciences to post $-7 EPS for the current fiscal year and $-8 EPS for the next fiscal year.
Assembly Biosciences Trading Up 13.0%
Shares of Assembly Biosciences stock traded up $2.75 during trading on Friday, hitting $23.97. 480,844 shares of the stock traded hands, compared to its average volume of 38,031. The firm has a market cap of $183.13 million, a P/E ratio of -4.30 and a beta of 0.64. Assembly Biosciences has a 52-week low of $7.75 and a 52-week high of $23.97. The stock's fifty day simple moving average is $17.99 and its 200 day simple moving average is $14.00.
Hedge Funds Weigh In On Assembly Biosciences
A hedge fund recently raised its stake in Assembly Biosciences stock. Acadian Asset Management LLC increased its position in shares of Assembly Biosciences, Inc. (NASDAQ:ASMB - Free Report) by 42.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 23,027 shares of the biopharmaceutical company's stock after buying an additional 6,823 shares during the period. Acadian Asset Management LLC owned about 0.30% of Assembly Biosciences worth $219,000 at the end of the most recent quarter. Institutional investors own 19.92% of the company's stock.
About Assembly Biosciences
(
Get Free Report)
Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.
Further Reading
Before you consider Assembly Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Assembly Biosciences wasn't on the list.
While Assembly Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
